



Published in final edited form as:

HIV Med. 2012 May ; 13(5): 264–275. doi:10.1111/j.1468-1293.2011.00970.x.

Metabolic Abnormalities and Viral Replication is Associated with Biomarkers of Vascular Dysfunction in HIV-Infected Children

Tracie L. Miller, MD¹, William Borkowsky, MD², Linda A. DiMeglio, MD, MPH³, Laurie Dooley⁴, Mitchell E. Geffner, MD⁵, Rohan Hazra, MD⁶, Elizabeth J. McFarland, MD⁷, Armando J. Mendez, PhD⁸, Kunjal Patel, DSc, MPH⁹, George K. Siberry, MD, MPH⁶, Russell B. Van Dyke, MD¹⁰, Carol J. Worrell, MD⁶, and Denise L. Jacobson, PhD, MPH⁹ for the Pediatric HIV/AIDS Cohort Study (PHACS)

¹Divisions of Pediatric Clinical Research, Department of Pediatrics, Miller School of Medicine at the University of Miami, Miami FL

²New York University School of Medicine, New York, NY

³Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis IN

⁴Frontier Science and Technology Research Foundation, Amherst, NY

⁵Saban Research Institute of Childrens Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles CA

⁶*Eunice Kennedy Shriver* National Institute of Child Health and Human Development

⁷Department of Pediatrics, University of Colorado Denver School of Medicine, Denver CO

⁸Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, Miller School of Medicine at the University of Miami, Miami FL

⁹Department of Epidemiology, Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA

¹⁰Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, LA

Abstract

Please address all correspondence to: Tracie L. Miller, MD, Division of Pediatric Clinical Research, Department of Pediatrics (D820), Miller School of Medicine at the University of Miami, Batchelor Children's Research Institute, PO Box 016820, Miami, FL 33101, Phone: (305)-243-1423, Facsimile: (305)-243-8475, tracie.miller@miami.edu.

Presented at the Conference on Retroviruses and Opportunistic Infections, Montreal, Canada 2009

Conflicts of Interest:

The authors have no potential, perceived, or real conflicts of interest.

The following authors have contributed to the manuscript:

Tracie L. Miller: concept, design, analysis, manuscript preparation

William Borkowsky: design, manuscript preparation

Linda A. DiMeglio: design, manuscript preparation

Laurie Dooley: manuscript preparation

Mitchell E. Geffner: concept, design, analysis, manuscript preparation

Rohan Hazra: concept, design, analysis, manuscript preparation

Elizabeth J. McFarland: concept, design, analysis, manuscript preparation

Armando J. Mendez: analysis, manuscript preparation

Kunjal Patel: concept, design, analysis, manuscript preparation

George K. Siberry: concept, design, analysis, manuscript preparation

Russell B. VanDyke: concept, design, analysis, manuscript preparation

Carol J. Worrell: concept, analysis, manuscript preparation

Denise L. Jacobson: concept, design, analysis, manuscript preparation

Objectives—Human immunodeficiency virus (HIV)-infected children may be at risk for premature cardiovascular disease. We compared levels of biomarkers of vascular dysfunction among HIV-infected children with and without hyperlipidemia to HIV-exposed, uninfected children (HEU) enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS), and determined factors associated with these biomarkers.

Design—Prospective cohort study

Methods—Biomarkers of inflammation (C-reactive protein (CRP), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP1)); coagulant dysfunction (fibrinogen and P-selectin); endothelial dysfunction (soluble intracellular cell adhesion molecule-1 (sICAM), soluble vascular cell adhesion molecule-1 (sVCAM), and E-selectin); and metabolic dysfunction (adiponectin) were measured in 226 HIV-infected and 140 HEU children. Anthropometry, body composition, lipids, glucose, insulin, HIV disease severity, and antiretroviral therapy were recorded.

Results—The median ages were 12.3 y (HIV-infected) and 10.1 y (HEU). Body mass index (BMI) Z-scores, waist and hip circumference, and percent body fat were lower among HIV-infected. Total and non-HDL cholesterol and triglycerides were higher in HIV-infected children. HIV-infected children had higher MCP-1, fibrinogen, sICAM, and sVCAM levels. In multivariable analyses in the HIV-infected children alone, BMI z-score was associated with higher CRP and fibrinogen, but lower MCP-1 and sVCAM. Unfavorable lipid profiles were positively associated with IL6, MCP1, fibrinogen, and P- and E-selectin, whereas increased HIV viral load was associated with markers of inflammation (MCP1 and CRP) and endothelial dysfunction (sICAM and sVCAM).

Conclusions—HIV-infected children have higher levels of biomarkers of vascular dysfunction than do HEU children. Risk factors associated with higher biomarkers include unfavorable lipid levels and active HIV replication.

Keywords

Children; HIV/AIDS; vascular dysfunction; cardiovascular risk factors; biomarkers

INTRODUCTION

Effective antiretroviral (ARV) regimens for human immunodeficiency virus (HIV) infection have increased life expectancy, and many now live for decades with chronic illness.[1] Long-term complications are emerging as the greatest challenges facing HIV-infected individuals. Atherosclerotic cardiovascular disease (CVD) is a leading co-morbidity and cause of mortality among HIV-infected adults.[2] Several studies show that HIV-infected children, compared to healthy peers, have higher rates of CVD risk factors, including dyslipidemia, insulin resistance, obesity and central adiposity.[3–7] HIV infection also results in prolonged chronic inflammation, thereby increasing CVD risk. Exogenous obesity, common among perinatally HIV-infected youth, can also contribute to CVD risk.[8, 9] For perinatally-infected children, these exposures start *in utero* and continue through critical periods of growth, puberty, and development.

Inflammation, now considered the primary mechanism leading to atherosclerosis, can initiate a complex sequence of events that eventually produce detectable arterial changes and symptomatic CVD.[10] A host of cellular pathways are activated through inflammation, with most being initiated through injury to the endothelium.[10] Factors associated with endothelial injury include oxidized cholesterol, hyperglycemia, lifestyle (smoking), and familial/genetic risks.[11] In HIV-infected patients, the effects of chronic immune activation from HIV infection [12, 13] and potential oxidative stress (induced by mitochondrial dysfunction) due to highly active antiretroviral therapy (HAART) also come into play.[14,

15] These factors initiate a cascade of events that can increase inflammation and produce changes in endothelial function and/or coagulation status.

Although HIV-infected children carry risk factors that are associated with premature atherosclerotic CVD, it is currently difficult to ascertain whether the adverse CVD outcomes attributed to HIV infection in adults will be observed as HIV-infected children age. Emerging evidence from large, long-term, and prospective studies on CVD risk in non-HIV healthy children[16, 17] show that risk factors tracked from early childhood are associated with adverse CVD outcomes in adulthood. Studies that show direct evidence of vascular inflammation may provide further proof of increased CVD risk that, in turn, may ultimately lead to new, preventive interventions for these children. C-reactive protein (CRP) is one of the best-studied measures of systemic inflammation and high levels can predict adverse CVD outcomes in adults.[18] A number of other biomarkers are associated with more specific changes in these inflammatory pathways in both HIV-infected and HIV-uninfected populations.[19–21]

We have previously determined that HIV-infected children have increased levels of biomarkers of vascular dysfunction,[22] yet little work has been done to compare these levels to those of HIV-exposed, uninfected (HEU) children or to determine the potential associations of biomarker levels with metabolic factors such as lipids and insulin resistance. We hypothesized that HIV-infected children with hyperlipidemia have higher levels of selected biomarkers associated with vascular inflammation pathways compared to HIV-infected children without hyperlipidemia and HEU children (with and without hyperlipidemia). Furthermore, we sought to determine whether metabolic, anthropometric, and disease- or treatment-specific factors are associated with higher levels of these biomarkers.

METHODS

Study Population and Participants

Participants were enrolled in the Adolescent Master Protocol (AMP), part of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development-supported Pediatric HIV/AIDS Cohort Study (PHACS). Eligible children were between 7 and 16 years and born to HIV-infected mothers. The AMP study has enrolled 451 children with perinatal HIV-infection and 227 HEU. Enrollment began March 2007 at 15 sites in the US and Puerto Rico, and completed recruitment in December 2009. The overall aims of the prospective PHACS study are to determine the impact of HIV infection and ARV therapy on several clinical outcomes in pre-adolescents and adolescents, including growth, nutrition, and cardio-metabolic risk.

The PHACS protocol requires that all HIV-infected children have fasting lipids measured annually. The protocol also requires that repository specimens be drawn at the entry visit on all participants. As these are pediatric patients, the amount of specimen varies across individuals. As of August 2009, there were 357 HIV-infected children enrolled in the study who had fasting lipids at the entry visit and 184 HEU with an entry visit. We determined that 226 of 357 HIV-infected children and 140 of 184 children had an adequate volume of repository specimen to assay for vascular biomarkers. Among the HIV-infected children, we defined hyperlipidemia by the modified National Cholesterol Education Program (NCEP) criteria [total cholesterol >200 mg/dL, LDL-cholesterol >130 mg/dL, triglycerides >110 mg/dL (≤ 9 y) or >150 mg/dL (≥ 10 y), or HDL-cholesterol <35 mg/dL][23]. Among the 357 HIV-infected children (all eligible children), 41% met the dyslipidemia definition. In our subsample of 226 (those included in this analysis), 39% met the hyperlipidemia definition.

Our subsample was similar by age, sex, race, CD4 category, and BMI z-score when compared to children who did not have repository samples.

The Institutional Review Boards at all clinical sites and the Harvard School of Public Health (Statistical and Data Management Center) approved the protocol, and informed consent from the parent(s) or guardian(s), and assent from the participants (when appropriate) were obtained.

Data Collection

At the first study visit in AMP, clinical information was collected including age, sex, race, Tanner stage (by physical examination), and family history of diabetes, atherosclerosis, myocardial infarction, and hyperlipidemia. Weight and height were measured and body mass index (BMI) was calculated [weight (kg)/ height² (m²)] and expressed as z-scores.[24] Waist and hip circumferences were measured with a non-stretchable plastic tape measure. Waist and hip circumference were measured according to standard methods.[25] Anthropometric measures were standardized by training sessions conducted by a registered dietitian experienced in anthropometry during the annual PHACS meeting. Percent body fat was calculated from a total body dual-energy X-ray absorptiometry (DXA) scan performed on either a Lunar (General Electric Healthcare, UK) or Hologic (Hologic Inc, Bedford, MA) scanner according to standard methods.[26] Scans were sent to the Body Composition Analysis Center at Tufts University School of Medicine for central analysis and standardization.

Fasting serum levels of total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, glucose, and insulin were measured locally and in real-time at study entry for all HIV-infected children. Non-HDL cholesterol was calculated as the difference between total and HDL-cholesterol. In HEU children, plasma lipid and lipoproteins were measured by standard methods at the Diabetes Research Institute Clinical Chemistry Laboratory at the University of Miami, on a Cobas 6000 analyzer (Roche Diagnostics, Indianapolis, IN) using manufacturer's reagents and procedures. The homeostatic model assessment of insulin resistance (HOMA-IR) score was calculated: [fasting insulin (μU/mL) × fasting glucose (mmol/L)]/22.5.[27] For HIV-infected children only, concurrent Center for Disease Control (CDC) pediatric HIV disease stage,[28] absolute CD4+ T-lymphocyte cell (CD4) count, plasma HIV-1 RNA by quantitative PCR (viral load), and ARV regimens were recorded.

Biomarkers of Vascular Dysfunction

Fibrinogen and CRP were measured at a central laboratory by nephelometry on a Dade-Behring (Deerfield, IL) auto-analyzer using the manufacturer's reagents and instructions. Intra- and interassay coefficients of variation were 2.6% and 2.7%, respectively, for fibrinogen and 4.4% and 5.7%, respectively, for CRP. Adiponectin was measured by a double-antibody radioimmunoassay (Linco Research, St. Charles, MO), with intra- and inter-assay coefficients of variation both <5%. CRP values greater than 10 mg/dL were not used in the data analysis because high levels could be due to intercurrent infection.

Interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), soluble vascular cell adhesion molecule-1 (sVCAM), soluble intracellular cell adhesion molecule-1 (sICAM), soluble E-selectin, and soluble P-selectin were measured by enzyme-linked immunosorbent assay (ELISA) using reagents from R&D Systems (Minneapolis, MN). Intra- and interassay coefficients of variation were, respectively: IL-6, 6.8% and 9.4%; MCP-1 4.0% and <7.5%; sVCAM-1, 5.9% and 10.2%; sICAM-1, 4.8% and 10.1%; E-selectin, 5.0% and 8.8%; and P-selectin, 4.2% and 9.8%.

Statistical Methods

Unadjusted analysis—Using the Kruskal-Wallis test for continuous and Chi-square test for categorical variables, the four study groups were compared by age, sex, and race/ethnicity; Tanner stage; height, weight and BMI z-scores; lipids; and biomarkers of vascular dysfunction. For each biomarker, we evaluated differences between the four study groups by the Wilcoxon rank sum test.

Adjusted analyses—When waist:hip ratio, lipids, and biomarkers of vascular dysfunction were the outcome variable, they were \log_{10} transformed for analysis to normalize the distribution. When lipids were predictor variables, each lipid was categorized into quartiles based on the distribution in the HIV-infected children. Cutoffs were based on the distribution in the HIV-infected to be consistent across models because one set of models included only HIV-infected and another included HIV-infected and HEU (see analyses below).

We evaluated differences between all HIV-infected children and HEU children on anthropometric and lipid outcomes using multivariable general linear regression. Waist:hip ratio, percent body fat, and the lipid outcomes were adjusted for potential confounding by age, race/ethnicity, sex and Tanner stage, while weight, height, and BMI z-score were adjusted for race/ethnicity and Tanner stage only because z-scores are standardized for age and sex.

We compared levels of each biomarker of vascular dysfunction in the four study groups by multivariable linear regression adjusted for sex, age, race/ethnicity, Tanner stage and BMI z-score. Among HIV-infected children only, we determined the association of each metabolic and HIV disease-specific variable including individual lipids, HIV viral load (≤ 400 , 400–5,000, and $>5,000$ copies/mL), CD4 count (<200 and ≥ 200 cells/mm³), CDC stage (N/A, B, and C), and current use or non-use of each ARV class (protease inhibitor, PI; non-nucleoside reverse transcriptase inhibitor, NNRTI; and nucleoside reverse transcriptase inhibitor, NRTI) separately with each biomarker outcome adjusted for age, sex, race/ethnicity, and BMI z-score. Variables significant at $p \leq 0.1$ or were confounders were retained in the final model. Models were examined for influential points using standardized residuals and assumptions of linearity between age and BMI z-score were evaluated. For presentation, the antilog was taken for each beta coefficient and 95% confidence interval (95% CI) in each model. The interpretation of the antilog is as follows: if the estimate presented for HIV-infected versus HEU was 0.9 in the model of CRP, the interpretation would be that the average CRP in the HIV-infected is 0.9 times the average in the HEU, or 9% lower in the HIV-infected. For categorical variables that were significant at $p \leq 0.05$ on the F-test, we show the Wald p-value for differences between each level versus the reference level. All analyses were performed in SAS 9.1 (SAS Institute, Cary, NC).

RESULTS

Demographic and Clinical Characteristics

In this analysis, we studied a subset of AMP participants including 226 HIV-infected children (89 who met the hyperlipidemia definition) and 140 HEU (40 who met the hyperlipidemia definition). In the HEU, 28.6% met the hyperlipidemia definition. The clinical characteristics of the four groups are shown in Table 1. HIV-infected children were significantly older than HEU and a greater proportion was non-Hispanic black. As expected because of their younger age, HEU children were more likely to be prepubertal (Tanner 1) than HIV-infected children. In the HIV-infected group, 76% had CD4 counts >500 cells/mm³, 65% had an HIV viral load ≤ 400 copies/mL, and 72% were on HAART with a

protease inhibitor. The percent that ever used the following medications and the median duration of use are as follows: indinavir (7%, 2.0 yrs); atazanavir (13%, 1.9 yrs); boosted PI (66%; 4.3 yrs); abacavir (36%, 2.4 yrs); and stavudine (79%; 6.2 yrs).

Table 1 also shows differences in anthropometric and metabolic (unadjusted) outcomes between the four groups. HIV-infected children had lower weight, height and BMI z-scores than the HEU; there were no differences between the two HIV groups. HIV-infected children without hyperlipidemia were more likely to have a family member with diabetes than the HEU children and HIV-infected children with hyperlipidemia (23% vs 12%, $p=0.004$; 23% vs 11%, $p=0.09$, respectively), although other familial risk factors were similar (atherosclerosis, myocardial infarction, and hypercholesterolemia; data not shown).

Table 2 compares adjusted anthropometric and metabolic parameters potentially associated with vascular inflammation by HIV status. The mean adjusted z-scores were lower in HIV-infected compared to HEU for weight (-0.77 SD), height (-0.76 SD), and BMI (-0.49 SD) ($p<0.001$ for all comparisons). Mean adjusted waist and hip circumferences were each almost 5 cm smaller in the HIV-infected children, although the waist:hip ratio was similar between groups. Total body fat was about 4.7% lower in HIV-infected children. In a similar analysis, after adjusting for age, race, sex, Tanner stage, and BMI z-score, HIV-infected children had 1.05 times (or 5%) higher total cholesterol, 1.08 (or 8%) higher non-HDL cholesterol, and 1.32 (or 32%) higher level of triglycerides than HEU.

Comparisons of Biomarkers of Vascular Dysfunction by HIV Status

Table 3 shows the median (25th, 75th) of the raw (unadjusted) values and comparisons of the biomarkers of vascular dysfunction across all four groups with the pair-wise comparisons between each group. MCP-1 and fibrinogen were the highest in HIV-infected children with hyperlipidemia and there were no differences between the other groups. P-selectin was the lowest among HIV-infected children who did not have hyperlipidemia, but there were no differences among the other groups. sVCAM was highest in the HIV-infected group, regardless of lipid status and E-selectin appeared to be highest in those with hyperlipidemia, regardless of HIV status. Table 4 shows differences between all 4 groups for each biomarker after adjusting for age, sex, race, tanner stage and BMI z-score. HIV-infected children had higher levels of MCP-1, fibrinogen, and sVCAM regardless of lipid status. In addition, sICAM was elevated in HIV-infected children without hyperlipidemia compared to the reference group. The analyses were adjusted for other demographic and clinical factors (data not shown in the Table). We found age was positively associated with CRP, IL-6, and fibrinogen; Hispanic and NHB ethnicity was positively association with fibrinogen; and BMI z-score was positively associated with CRP, IL-6, and fibrinogen.

Correlates of Biomarkers of Vascular Dysfunction in HIV-infected Children

For the HIV-infected children only, we analyzed clinical correlates (including HIV disease-specific measures) of each biomarker of vascular dysfunction in a multivariable model (Table 5). Results for adiponectin are not shown because, other than age and HOMA-IR (known associations), it was not independently associated with any other variables. In general, there were few associations between any of these biomarkers and age and sex, although differences were found by race/ethnicity. Compared to non-Hispanic whites, Hispanics had higher levels of the biomarkers of inflammation (CRP and IL-6) while non-Hispanic blacks had lower levels of MCP-1. Non-Hispanic blacks also had higher levels of fibrinogen, lower levels of P-selectin (measures of coagulant dysfunction and inflammation), and lower levels of sICAM. A higher BMI z-score was associated with higher CRP and fibrinogen and lower MCP-1 and sVCAM. Unfavorable lipid profiles were generally associated with higher levels of these biomarkers of vascular dysfunction. Total

cholesterol was positively associated with P-selectin and E-selectin; LDL-cholesterol was positively associated with fibrinogen; and triglycerides were positively associated with MCP-1. HDL-cholesterol levels were inversely related to IL-6.

Viral load was positively associated with MCP-1 and biomarkers more specific for endothelial dysfunction including sICAM, and sVCAM. Current PI and NNRTI exposures were associated with higher levels of fibrinogen and CRP, respectively. Current NRTI exposure was associated with lower levels of E-selectin. No significant relationships were found for waist or hip circumference, waist:hip ratio, total body fat, HOMA-IR, or CD4 and all biomarkers.

DISCUSSION

Our study shows that biomarkers associated with different pathways of atherosclerosis - inflammation and coagulation and endothelial dysfunction - were higher in HIV-infected children compared HEU children. In the HIV-infected children, elevations of these biomarkers were independent of metabolic factors (hyperlipidemia or insulin resistance), with the exception of the selectins (both P and E), where differences appeared to be influenced strongly by lipid levels. Biomarkers of endothelial dysfunction, sICAM and sVCAM, and biomarkers of inflammation, CRP and MCP-1, were associated with higher HIV viral loads.

Atherosclerosis is considered an inflammatory process.[29] Triggers that can initiate vascular injury include lipids, lipoproteins, angiotensin II, cytokines, glycosylation products, oxidative stress, and infectious agents.[11] This injury results in the activation of nuclear factor- κ B (NF- κ B) with several pro-inflammatory cytokines released including molecules that increase leukocyte rolling and adherence to the endothelium, leukocyte migration through the endothelium, and recruitment of more inflammatory cells. Activated macrophages secrete several cytokines and growth factors that promote maturation of the atheromatous lesion.

Biomarkers such as hsCRP are independent predictors of future CVD in adults and there is emerging evidence of their utility in children.[18, 30] Other biomarkers that reflect leukocyte adherence, migration, and chemotaxis have also been associated with increased CVD risk in HIV-uninfected populations.[19, 20] We found that CRP and MCP-1, biomarkers associated with inflammation, were associated with increased viral load. In the Strategic Management of Antiretroviral Therapy (SMART) study, hsCRP and IL-6 levels were associated with viral load and CVD all-cause mortality risk in HIV-infected adults.[31] Even in patients with viral suppression, the levels of these biomarkers were about 40–60% higher than in an HIV-uninfected population.[32] However, not all studies have shown that hsCRP levels are associated with adverse CVD events.[33]

HDL-cholesterol and higher triglycerides were associated with biomarkers of inflammation although the HDL effect was diminished in the HIV model when viral load was considered. HDL-cholesterol, thought to be critical in the “reverse transport” of cholesterol from arterial plaques, may also have direct anti-inflammatory effects[34] by decreasing E-selectin[35] (associated with leukocyte tethering and rolling) and limiting expression of vascular adhesion molecules such as VCAM and ICAM.[36] Other studies show that postprandial triglycerides or triglyceride-rich lipoproteins are associated with activation of NF- κ B[37] or that very-low-density-lipoproteins (VLDL) can increase expression of leukocyte adhesion factors.[38] We found that triglycerides were associated with higher MCP-1 and E-selectin. The putative role of selectins is to facilitate the tethering and rolling of leukocytes along the endothelium; hyperlipidemia may induce endothelial injury and activate this process. Both

P- and E-selectin levels were associated with hyperlipidemia, even after adjusting for HIV status.

Although a hypercoagulable state is associated with CVD risk, few studies have evaluated biomarkers associated with thrombosis in HIV-infected patients. Fibrinogen is positively associated with mortality in HIV,[31] but whether this translates to increased CVD risk is unclear. PI therapy is associated with increased fibrinogen levels in the Fat Redistribution and Metabolic Change Study (FRAM).[39] We found fibrinogen was positively correlated with LDL-cholesterol levels in HIV-infected children. Fibrinogen may represent coagulation risk, but may also reflect inflammation.

Several studies in adults report associations between endothelial dysfunction markers with HIV disease severity.[40, 41] We found that MCP-1, sICAM, and sVCAM levels were higher in the HIV-infected children compared to HEU and that higher levels were associated with viral load, independent of metabolic status. These findings suggest that HIV itself may cause immune activation and resulting endothelial injury.[41] These biomarkers are associated with all-cause mortality in non-HIV populations[42] and sVCAM levels are associated with increased carotid intima media thickness (cIMT) in HIV-infected adults.[43] The HIV *tat* and *nef* proteins induce VCAM-1, ICAM-1, and MCP-1. ICAM was elevated in HIV-infected children compared to controls and elevations were inversely related to CD4 counts.[44] In addition MCP-1 is proposed to activate viral infection.[45] Treatment interruptions are associated with increased levels of sVCAM, ICAM, and P-selectin,[46] suggesting the influence of viral activity on expression of these biomarkers.

We did not find a strong effect of ARVs on the biomarkers we studied due possibly to the collinearity of ARVs on metabolic outcomes. PI therapy was associated with higher fibrinogen and NNRTI was associated with higher CRP. In cell culture, ARVs can alter endothelial cell mitochondrial DNA thereby increasing production of reactive oxygen species,[47, 48] endothelial cell permeability,[49] and leukocyte adhesion[50]. Thus, ARV therapy could directly or indirectly (through changes in the metabolic profile) increase levels of biomarkers.

Studies on vascular inflammation and structural/functional vascular dysfunction (*i.e.*, vessel compliance, distensibility, and structure) in HIV-infected children have been limited.[51–56] We have recently shown that similar biomarkers are also associated with central adiposity and decreased immune function (lower CD4 counts), although we had limited ability to evaluate the effect of lipids on these biomarkers.[22] Some studies show vascular stiffness (through flow-mediated dilation studies) and cIMT were greater in HIV-infected children than controls[53–55] with differences independent of known CVD risk factors and ARV therapy,[53] while others show an association with ARVs, especially PIs.[52, 54, 55] Longitudinal follow-up in one study revealed cIMT was similar in HIV and controls.[51, 56] Interestingly, some pre-HAART studies in children showed increased coronary artery calcifications,[57] suggesting the contribution of baseline immune activation to CVD risk.

We did find some unexpected results. For instance, BMI was inversely related to sVCAM. In non-HIV cohorts, adiposity is associated with higher levels of these biomarkers.[58] However, in our cohort, we suspect that higher viral loads (sicker children) were associated with lower BMI and, in turn, higher viral loads were associated with many of our biomarkers including sVCAM. We also selected our groups by whether the child met a hyperlipidemia definition and our groups may not represent HIV as a whole. However, the rates of hyperlipidemia in the PHACS cohort as a whole were similar to our study sample. Lastly, we did find that children with hyperlipidemia were more likely to have a family member with diabetes. This is an unusual association and may be a result of reporting bias.

In conclusion, we show that biomarkers associated with vascular inflammatory pathways are increased in HIV-infected children when compared to appropriately matched HEU children. Higher levels of these biomarkers were independently associated with HIV viral load (MCP-1, sICAM and sVCAM) and/or hyperlipidemia (MCP-1, fibrinogen, P-selectin and E-selectin). Our findings provide further evidence that HIV-infected children are at risk for CVD. Since many of these biomarkers were associated with modifiable risk factors, such as hyperlipidemia, interventions to modify these risks should be considered in future studies.

Acknowledgments

Sources of Funding: The study was supported by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development with co-funding from the National Institute of Allergy and Infectious Diseases, the National Institute on Drug Abuse, the National Institute of Mental Health, the National Institute of Deafness and Other Communication Disorders, the National Heart Lung and Blood Institute, National Institute of Neurological Disorders and Stroke, and the National Institute on Alcohol Abuse and Alcoholism, through cooperative agreements with the Harvard University School of Public Health (U01 HD052102-04) (Principal Investigator: George R. Seage, III; Project Director: Julie Alperen) and the Tulane University School of Medicine (U01 HD052104-01) (Principal Investigator: Russell B. Van Dyke; Co-Principal Investigator: Kenneth Rich; Project Director: Patrick Davis). Data management services were provided by Frontier Science and Technology Research Foundation (PI: Suzanne Siminski), and regulatory services and logistical support were provided by Westat, Inc. (PI: Mercy Swatson). This study was supported by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780. Its contents are the authors' sole responsibility.

We thank the children and families for their participation in the PHACS Adolescent Master Protocol (AMP), and the individuals and institutions involved in the conduct of PHACS AMP.

The following institutions, clinical site investigators, and staff participated in conducting PHACS AMP in 2009, in alphabetical order: **Baylor College of Medicine:** William Shearer, Norma Cooper, Lynette Harris; **Bronx Lebanon Hospital Center:** Murli Purswani, Mahboobullah Baig, Anna Cintron; **Children's Diagnostic & Treatment Center:** Ana Puga, Sandra Navarro, Doyle Patton; **Children's Hospital, Boston:** Sandra Burchett, Nancy Karthas, Betsy Kammerer; **Children's Memorial Hospital:** Ram Yogeve, Kathleen Malee, Scott Hunter, Eric Cagwin; **Jacobi Medical Center:** Andrew Wiznia, Marlene Burey, Molly Nozyce; **St. Christopher's Hospital for Children:** Janet Chen, Elizabeth Gobs, Mitzie Grant; **St. Jude Children's Research Hospital:** Katherine Knapp, Kim Allison, Patricia Garvie; **San Juan Hospital/Department of Pediatrics:** Midnela Acevedo-Flores, Heida Rios, Vivian Olivera; **Tulane University Health Sciences Center:** Margarita Sillio, Cheryl Borne, Patricia Sirois; **University of California, San Diego:** Stephen Spector, Kim Norris, Sharon Nichols; **University of Colorado Denver Health Sciences Center:** Elizabeth McFarland, Emily Barr, Carrie Chambers; **University of Maryland, Baltimore:** Douglas Watson, Nicole Messenger, Rose Belanger; **University of Medicine and Dentistry of New Jersey:** Arry Dieudonne, Linda Bettica, Susan Aduabato; **University of Miami:** Gwendolyn Scott, Lisa Himic, Elizabeth Willen

REFERENCES

1. Laufer M, Scott GB. Medical management of HIV disease in children. *Pediatr Clin North Am.* 2000; 47:127–153. [PubMed: 10697645]
2. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. *Circulation.* 2008; 118:198–210. [PubMed: 18566320]
3. Arpadi SM, Bethel J, Horlick M, Sarr M, Bamji M, Abrams EJ, et al. Longitudinal changes in regional fat content in HIV-infected children and adolescents. *AIDS.* 2009
4. Bitnun A, Sochett E, Dick PT, To T, Jefferies C, Babyn P, et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. *J Clin Endocrinol Metab.* 2005; 90:168–174. [PubMed: 15483082]
5. Miller TL, Grant YT, Almeida DN, Sharma T, Lipshultz SE. Cardiometabolic disease in human immunodeficiency virus-infected children. *J Cardiometab Syndr.* 2008; 3:98–105. [PubMed: 18453810]

6. Miller TL, Orav EJ, Lipshultz SE, Arheart KL, Duggan C, Weinberg GA, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. *J Pediatr*. 2008; 153:491–497. [PubMed: 18538789]
7. Sanchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De Jose Gomez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. *Eur J Pediatr*. 2005; 164:271–276. [PubMed: 15650834]
8. Reiss AB. Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. *Curr Rheumatol Rep*. 2009; 11:255–260. [PubMed: 19691928]
9. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. *Diabetologia*. 2010; 53:1270–1287. [PubMed: 20361178]
10. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. *J Am Coll Cardiol*. 2009; 54:2129–2138. [PubMed: 19942084]
11. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. *Clin Chem*. 2008; 54:24–38. [PubMed: 18160725]
12. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med*. 2003; 349:1993–2003. [PubMed: 14627784]
13. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. *N Engl J Med*. 2007; 356:1723–1735. [PubMed: 17460226]
14. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. *Free Radic Biol Med*. 1995; 19:523–528. [PubMed: 7590404]
15. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. *J Acquir Immune Defic Syndr*. 2009; 51:268–273. [PubMed: 19387353]
16. McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. *Circulation*. 2008; 117:1216–1227. [PubMed: 18316498]
17. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. *Circulation*. 2009; 119:3078–3084. [PubMed: 19506114]
18. de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. *Cardiovasc Pathol*. 2007; 16:14–21. [PubMed: 17218210]
19. Bonaterra GA, Zugel S, Kinscherf R. Novel systemic cardiovascular disease biomarkers. *Curr Mol Med*. 2010; 10:180–205. [PubMed: 20196728]
20. Baker JV, Duprez D. Biomarkers and HIV-associated cardiovascular disease. *Curr Opin HIV AIDS*. 2010; 5:511–516. [PubMed: 20978394]
21. Worm SW, Hsue P. Role of biomarkers in predicting CVD risk in the setting of HIV infection? *Curr Opin HIV AIDS*. 2010; 5:467–472. [PubMed: 20978389]
22. Miller TL, Somarriba G, Orav EJ, Mendez AJ, Neri D, Schaefer N, et al. Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1. *J Acquir Immune Defic Syndr*. 2010; 55:182–188. [PubMed: 20531209]
23. Hickman TB, Briefel RR, Carroll MD, Rifkind BM, Cleeman JI, Maurer KR, Johnson CL. Distributions and trends of serum lipid levels among United States children and adolescents ages 4–19 years: data from the Third National Health and Nutrition Examination Survey. *Prev Med*. 1998; 27:879–890. [PubMed: 9922071]
24. Kuczumski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States. *Adv Data*. 2000:1–27. [PubMed: 11183293]
25. [Accessed December 1, 2010] National Health and Nutrition Examination Survey III Body Measurements (Anthropometry). 2010. <http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/anthro.pdf>
26. Margulies L, Horlick M, Thornton JC, Wang J, Ioannidou E, Heymsfield SB. Reproducibility of pediatric whole body bone and body composition measures by dual-energy X-ray absorptiometry using the GE Lunar Prodigy. *J Clin Densitom*. 2005; 8:298–304. [PubMed: 16055960]

27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985; 28:412–419. [PubMed: 3899825]
28. Caldwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, Rogers MF. Revised Classification System for Human Immunodeficiency Virus Infection in Children Less Than 13 Years of Age. *MMWR CDC Surveill Summ*. 1994; 43:1–10.
29. Libby P. Inflammation in atherosclerosis. *Nature*. 2002; 420:868–874. [PubMed: 12490960]
30. Thomas NE, Baker JS, Graham MR, Cooper SM, Davies B. C-reactive protein in schoolchildren and its relation to adiposity, physical activity, aerobic fitness and habitual diet. *Br J Sports Med*. 2008; 42:357–360. [PubMed: 18178678]
31. Kuller LH, Tracy R, Bellosso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. *PLoS Med*. 2008; 5:e203. [PubMed: 18942885]
32. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. *J Infect Dis*. 2010; 201:1788–1795. [PubMed: 20446848]
33. Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. *AIDS*. 2010; 24:1509–1517. [PubMed: 20505494]
34. Choudhury RP, Rong JX, Trogan E, Elmalem VI, Dansky HM, Breslow JL, et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. *Arterioscler Thromb Vasc Biol*. 2004; 24:1904–1909. [PubMed: 15319266]
35. Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. *Circulation*. 2001; 103:108–112. [PubMed: 11136694]
36. Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. *Arterioscler Thromb Vasc Biol*. 1998; 18:1450–1455. [PubMed: 9743234]
37. Dichtl W, Nilsson L, Goncalves I, Ares MP, Banfi C, Calara F, et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. *Circ Res*. 1999; 84:1085–1094. [PubMed: 10325246]
38. Ting HJ, Stice JP, Schaff UY, Hui DY, Rutledge JC, Knowlton AA, et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. *Circ Res*. 2007; 100:381–390. [PubMed: 17234968]
39. Madden E, Lee G, Kotler DP, Wanke C, Lewis CE, Tracy R, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. *AIDS*. 2008; 22:707–715. [PubMed: 18356600]
40. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. *J Infect Dis*. 2002; 185:456–462. [PubMed: 11865397]
41. de Larranaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. *Thromb Res*. 2003; 110:93–98. [PubMed: 12893023]
42. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. *N Engl J Med*. 2000; 342:1792–1801. [PubMed: 10853003]
43. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. *Clin Infect Dis*. 2009; 49:1119–1127. [PubMed: 19712036]
44. Gaddi E, Laucella S, Balbaryski J, Cantisano C, Barboni G, Candi M, Giraudi V. Prognostic value of soluble intercellular adhesion molecule-1 (s-ICAM-1) in HIV-infected children. *Scand J Immunol*. 2000; 52:628–633. [PubMed: 11119270]

45. Vicenzi E, Alfano M, Ghezzi S, Gatti A, Veglia F, Lazzarin A, et al. Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1. *J Leukoc Biol.* 2000; 68:405–412. [PubMed: 10985258]
46. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. *AIDS.* 2009; 23:929–939. [PubMed: 19425222]
47. Jiang B, Hebert VY, Li Y, Mathis JM, Alexander JS, Dugas TR. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. *Toxicol Appl Pharmacol.* 2007; 224:60–71. [PubMed: 17669453]
48. Zhong DS, Lu XH, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. *Arterioscler Thromb Vasc Biol.* 2002; 22:1560–1566. [PubMed: 12377730]
49. Chen C, Lu XH, Yan S, Chai H, Yao Q. HIV protease inhibitor ritonavir increases endothelial monolayer permeability. *Biochem Biophys Res Commun.* 2005; 335:874–882. [PubMed: 16105660]
50. Mondal D, Pradhan L, Ali M, Agrawal KC. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. *Cardiovasc Toxicol.* 2004; 4:287–302. [PubMed: 15470276]
51. Ross AC, Storer N, O'Riordan MA, Dogra V, McComsey GA. Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. *Pediatr Infect Dis J.* 2010; 29:634–638. [PubMed: 20589981]
52. Charakida M, Loukogeorgakis SP, Okorie MI, Masi S, Halcox JP, Deanfield JE, Klein NJ. Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy. *Antivir Ther.* 2009; 14:1075–1079. [PubMed: 20032537]
53. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. *AIDS.* 2004; 18:1037–1041. [PubMed: 15096807]
54. Charakida M, Donald AE, Green H, Storry C, Clapson M, Caslake M, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. *Circulation.* 2005; 112:103–109. [PubMed: 15983247]
55. McComsey GA, O'Riordan M, Hazen SL, El-Bejjani D, Bhatt S, Brennan ML, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. *AIDS.* 2007; 21:921–927. [PubMed: 17457085]
56. Ross AC, O'Riordan MA, Storer N, Dogra V, McComsey GA. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. *Atherosclerosis.* 2010; 211:492–498. [PubMed: 20471650]
57. Perez-Atayde AR, Kearney DI, Bricker JT, Colan SD, Easley KA, Kaplan S, et al. Cardiac, aortic, and pulmonary arteriopathy in HIV-infected children: the Prospective P2C2 HIV Multicenter Study. *Pediatr Dev Pathol.* 2004; 7:61–70. [PubMed: 15255036]
58. Castro C, Tracy RP, Deckelbaum RJ, Basch CE, Shea S. Adiposity is associated with endothelial activation in healthy 2–3 year-old children. *J Pediatr Endocrinol Metab.* 2009; 22:905–914. [PubMed: 20020578]

Table 1

Clinical Characteristics by HIV Status and Hyperlipidemia

Variable	HIV+, hyperlipidemia N=89	HIV+, no hyperlipidemia N=137	HEU, hyperlipidemia N=40	HEU, no hyperlipidemia N=100	Overall P-value
Demographics and Anthropometrics - median (25th, 75th)[†]**					
Age (y)	12.3 ^{1,2} (10.0, 14.0)	12.3 ^{3,4} (10.0, 14.2)	9.6 ^{1,3} (8.5, 10.8)	10.5 ^{2,4} (8.2, 12.3)	<0.001
Male n, (%)	38 (43)	61 (54)	22 (55)	53 (53)	0.33
Race/ethnicity, n, (%)					<0.001
Non-Hispanic black	60 (67) ¹	109 (80) ^{2,3}	21 (53) ²	56 (56) ^{1,3}	
Hispanic	20 (22)	20 (15)	13 (33)	39 (39)	
Non-Hispanic white/other	9 (10)	8 (6)	6 (15)	5 (5)	
Tanner stage 1, n (%)	22 (25) ¹	37 (27) ^{2,3}	22 (55) ^{1,2}	38 (38) ³	0.004
Weight z-score	0.17 ^{1,2} (-0.58, 1.01)	0.18 ^{3,4} (-0.65, 0.87)	0.97 ^{1,3} (-0.17, 2.6)	0.52 ^{2,4} (-0.21, 1.7)	<0.001
Height z-score	-0.30 ^{1,2} (-1.30, 0.34)	-0.17 ^{3,4} (-1.05, 0.44)	0.30 ^{1,3} (-0.46, 1.0)	0.18 ^{2,4} (-0.48, 1.0)	<0.001
BMI z-score	0.45 ¹ (-0.32, 1.43)	0.15 ^{2,3} (-0.46, 1.02)	1.1 ^{1,2} (-0.1, 2.4)	0.75 ³ (-0.15, 1.7)	0.003
Total Cholesterol (mg/dL)	198 ^{1,2} (164, 218)	158 ^{1,3} (140, 177)	204 ^{3,4} (165, 216)	157 ^{2,4} (142, 172)	<0.001
LDL cholesterol (mg/dL)	113 ^{1,2} (81, 135)	87 ^{1,3} (73, 104)	126 ^{3,4} (95, 136)	90 ^{2,4} (72, 103)	<0.001
HDL cholesterol (mg/dL)	47 ^{1,2} (39, 56)	50 ¹ (43, 59)	47 (39, 59)	51 ² (44, 61)	0.045
Non HDL cholesterol (mg/dL)	146 ^{1,2} (116, 161)	104 ^{1,3} (90, 122)	141 ^{3,4} (124, 165)	103 ^{2,4} (87, 118)	<0.001

Variable	HIV +, hyperlipidemia N=89	HIV +, no hyperlipidemia N=137	HEU, hyperlipidemia N=40	HEU, no hyperlipidemia N=100	Overall P-value
Triglycerides (mg/dL)	151 ^{1,2,3} (107, 186)	75 ^{1,4} (54, 96)	112 ^{2,4,5} (59, 148)	64 ^{3,5} (55, 87)	<0.001
HOMA-IR	1.80 (1.00, 3.70)	1.5 (0.80, 2.95)			0.11
HIV-Specific Disease Characteristics					
CDC Stage, n (%)					0.32
Stage A, mildly symptomatic	23 (26)	49 (36)			
Stage B, moderately symptomatic	27 (30)	42 (31)			
Stage C, severely symptomatic	27 (30)	30 (22)			
Stage N, not symptomatic	12 (13)	15 (11)			
Absolute CD4 count (cells/mm ³), median (25th, 75th)	750 (530, 995)	704 (502, 902)			0.30
Viral load (copies/mL), median (25th, 75th)	223 (50, 871)	400 (50, 2677)			0.01
≤400 (%)	65 (73)	81 (59)			
401 – 5000 (%)	8 (9)	33 (24)			
>5000 (%)	16 (18)	23 (17)			
HAART-based ARV grouping, n (%)					0.04
HAART with PI	73 (82)	89 (65)			
HAART without PI	11 (12)	25 (18)			
Non-HAART ARV	3 (3)	9 (7)			
No ARV	2 (2)	12 (9)			

* Results with the same superscript are significantly different ($p \leq 0.05$) from each other

HEU = HIV-exposed, uninfected; IQR = interquartile range; ARV = antiretroviral therapy; CDC = Centers for Disease Control; PI = protease inhibitor; HAART = highly active antiretroviral therapy; LDL = low-density lipoprotein; HDL = high-density lipoprotein; HOMA-IR = homeostatic model assessment of insulin resistance

Table 2

Adjusted Anthropometric and Metabolic Measures in HIV-Infected Compared to HIV-Exposed but Uninfected (HEU) Children

Outcome*			
Anthropometric Outcomes	Mean Difference Between HIV-infected and HEU	95% CI	P-value
Weight z-score (SD)	-0.77	-1.07, -0.48	<0.001
Height z-score (SD)	-0.76	-1.02, -0.50	<0.001
BMI z-score (SD)	-0.49	-0.76, -0.22	<0.001
Body fat %	-4.67	-7.37, -1.97	<0.001
Waist circumference (cm)	-4.78	-7.84, -1.72	0.002
Hip circumference (cm)	-4.90	-7.88, -1.92	0.001
	HIV-infected relative to HEU***	95% CI	P-value
Waist:hip ratio	0.99	0.97, 1.01	0.24
Metabolic Outcomes**			
Total cholesterol	1.05	1.0, 1.11	0.04
LDL-cholesterol	1.03	0.96, 1.11	0.43
HDL-cholesterol	1.00	0.94, 1.05	0.89
Non-HDL cholesterol	1.08	1.01, 1.16	0.02
Total cholesterol/HDL	1.06	1.0, 1.13	0.06
Triglycerides	1.32	1.18, 1.48	<0.001

* Z-scores were adjusted for race/ethnicity and Tanner stage as they are already standardized for age and sex. All other outcomes were adjusted for age, sex, race, and Tanner stage. HEU is reference.

** Waist:hip ratio and all lipids were log₁₀ transformed for analysis and then exponentiated in the table.

*** As an example, the interpretation of the estimate for total cholesterol is that on average the HIV-infected have a 1.05 times greater (or 5% greater) total cholesterol value than the HEU.

BMI = body mass index; LDL = low-density lipoprotein; HDL = high-density lipoprotein

Table 3

Comparison of Biomarkers of Vascular Dysfunction among HIV-Infected with and without Hyperlipidemia and HIV-Exposed, but Uninfected (HEU) Children (Unadjusted)

Biomarker*	Median [25 th , 75 th]				Overall P-value**
	HIV HL N=89	HIV no HL N=137	HEU HL N=40	HEU no HL N=100	
Inflammation					
CRP (mg/L)	0.4 [0.20, 1.20]	0.4 [0.20, 1.10]	0.8 [0.30, 2.55]	0.5 [0.20, 2.20]	0.28
IL-6 (pg/mL)	1.1 [0.70, 1.65]	1.0 [0.70, 1.7]	1.2 [0.80, 2.40]	1.15 [0.65, 1.75]	0.33
MCP-1 (pg/mL)	106 [91, 142] ^{1,2,3}	101 [76, 131] ¹	97 [73, 125] ²	89 [74, 117] ³	0.004
Coagulant Dysfunction					
Fibrinogen (mg/dL)	381 [339, 421] ^{1,2}	355 [314, 398] ¹	360 [311, 415]	340 [292, 391] ²	0.001
P-selectin (ng/mL)	36.9 [27.2, 47.2] ¹	29.3 [22.6, 44.9] ^{1,2,3}	40.8 [28.9, 52.2] ²	35.3 [25.5, 51.2] ³	0.005
Endothelial Dysfunction					
sICAM (ng/mL)	280 [168, 341] ¹	283 [170, 338]	261 [164, 314]	241 [150, 321] ¹	0.12
sVCAM (ng/mL)	766 [659, 952] ^{1,2}	776 [667, 1040] ³	643 [540, 809] ^{1,3}	693 [581, 822] ²	<0.001
E-selectin (ng/mL)	51 [38.8, 64.8] ¹	41.3 [27.3, 59.3] ^{1,2,3}	61.7 [45.0, 76.9] ^{2,4}	48.0 [35.9, 68.0] ^{3,4}	<0.001
Metabolic Dysfunction					
Adiponectin (ng/mL)	9.0 [6.5, 11.3]	9.6 [7.6, 12.2]	8.7 [7.3, 11.2]	9.2 [7.8, 11.9]	0.26

* HL = hyperlipidemia; CRP = C-reactive protein; IL-6 = interleukin-6; MCP-1 = monocyte chemoattractant protein-1; sICAM = soluble intracellular cell adhesion molecule-1; sVCAM = soluble vascular cell adhesion molecule-1

** Overall P value from Kruskal-Wallis test for any difference across groups. Results with the same superscript are significantly different ($p \leq 0.05$) from each other based on the Wilcoxon test.

Multivariable Models of Biomarkers of Vascular Dysfunction among HIV-Infected and HIV-Exposed, but Uninfected (HEU) Children

Table 4

Covariate	Biomarker : Estimate [95% CI]**													
	CRP N=350		IL-6 N=363		MCP-1 N=364		Fibrinogen N=365		P-selectin N=363		sVCAM N=355		E-selectin N=365	
	Inflammation		Coagulant dysfunction		Endothelial dysfunction									
HIV Group														
HIV, HL	0.93 [0.66, 1.3]	1.01 [0.85, 1.3]	1.2 ³ [1.12, 1.4]	1.1 ³ [1.1, 1.2]	1.1 [0.92, 1.2]	1.11 [0.95, 1.3]	1.1 ² [1.04, 1.3]	1.1 [0.97, 1.3]	1.1 [0.92, 1.2]	1.1 [0.95, 1.3]	1.1 [0.97, 1.3]	1.1 [0.97, 1.3]	1.1 [0.97, 1.3]	1.1 [0.97, 1.3]
HIV, no HL	1.01 [0.73, 1.4]	0.97 [0.79, 1.2]	1.1 ¹ [1.01, 1.25]	1.1 [1.01, 1.1]	0.91 [0.8, 1.0]	1.2 ¹ [1.0, 1.4]	1.2 ³ [1.1, 1.3]	0.90 [0.79, 1.0]	0.91 [0.8, 1.0]	1.2 ¹ [1.0, 1.4]	1.2 ³ [1.1, 1.3]	1.1 [0.97, 1.3]	1.1 [0.97, 1.3]	1.1 [0.97, 1.3]
HEU, HL	1.1 [0.7, 1.8]	1.2 [0.94, 1.6]	1.06 [0.92, 1.22]	1.0 [0.97, 1.1]	1.1 [0.92, 1.3]	1.0 [0.85, 1.3]	0.97 [0.86, 1.1]	1.1 [0.93, 1.3]	1.1 [0.92, 1.3]	1.0 [0.85, 1.3]	0.97 [0.86, 1.1]	1.1 [0.93, 1.3]	1.1 [0.93, 1.3]	1.1 [0.93, 1.3]
HEU, no HL	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.
P-value	0.85	0.37	0.0015	<0.001	0.073	0.13	<0.001	0.004	0.073	0.13	<0.001	0.004	0.004	0.004

* Biomarkers of vascular dysfunction were log10-transformed for analysis. For presentation in the tables and text, the antilog was determined for each beta coefficient and 95% CI in each model. For example, for the outcome CRP in the table above, the estimate for HIV with HL vs. HEU no HL was 0.93. The interpretation is that the average value of CRP in the HIV-infected is 0.93 times that in the HEU or ~ 7% lower in the HIV-infected.

** **Bolded variables are significant at p≤0.05 on the F-test.** The superscript indicates p-values for the differences with the HEU no HL. ¹p≤0.05; ²p≤0.01; ³p≤0.001.

*** All models were adjusted for age, sex, race/ethnicity, Tanner stage and BMI z-score. Other measures of body composition that were considered for the adjustment: waist and hip circumference, waist:hip ratio, and percent body fat. The number included in each model differs due to missing variables and for CRP values greater than 10 were excluded.

CRP = c-reactive protein; IL-6 = interleukin-6; MCP-1 = monocyte chemoattractant protein-1; sVCAM = soluble intracellular cell adhesion molecule-1; sVCAM = soluble vascular cell adhesion molecule-1

Table 5
Multivariable Predictors of Biomarkers of Vascular Dysfunction among HIV-Infected Children

Covariate ***	Biomarker * Ratio [95% CI]**										
	Inflammation			Coagulant dysfunction			Endothelial dysfunction				
	CRP N=214	IL-6 N=224	MCP-1 N=224	Fibrinogen N=223	P-selectin N=224	sICAM N=224	svCAM N=222	E-selectin N=225			
Demographic											
Male (vs female)	0.94 [0.7, 1.27]	1.02 [0.84, 1.23]	1.07 [0.97, 1.18]	0.98 [0.93, 1.03]	0.98 [0.85, 1.12]	0.84¹ [0.71, 0.98]	1.0 [0.97, 1.1]	1.09 [0.95, 1.24]			
Age (y)	1.03 [0.97, 1.1]	1.03 [0.99, 1.07]	0.98 [0.96, 1.00]	1.01 [1.00, 1.02]	0.98 [0.95, 1.0]	0.97 [0.94, 1.00]	1.0 [0.98, 1.0]	0.97 [0.95, 1.00]			
Hispanic (vs NHW)	2.13¹ [1.11, 4.08]	1.59¹ [1.05, 2.41]	0.85 [0.69, 1.05]	1.10 [0.98, 1.24]	0.80 [0.59, 1.07]	0.76 [0.54, 1.08]	1.0 [0.86, 1.2]	1.13 [0.85, 1.5]			
NHBB (vs NHW)	1.17 [0.97, 3.01]	1.40 [0.97, 2.01]	0.74² [0.61, 0.89]	1.14¹ [1.03, 1.26]	0.73¹ [0.57, 0.94]	0.62² [0.46, 0.84]	0.95 [0.81, 1.1]	0.97 [0.76, 1.24]			
Anthropometric											
BMI Z-score	1.20² [1.05, 1.37]	1.02 [0.94, 1.11]	0.95² [0.90, 0.99]	1.04³ [1.02, 1.06]	1.01 [0.95, 1.08]	0.96 [0.90, 1.03]	0.96¹ [0.92, 1.0]	0.99 [0.93, 1.05]			
Metabolic[#]											
Total cholesterol	1.29² [1.07, 1.56]	1.49³ [1.24, 1.79]			
LDL cholesterol	1.11² [1.04, 1.20]			
HDL cholesterol	...	0.75¹ [0.56, 0.99]			
Triglycerides	1.24² [1.07, 1.42]			
HOMA-IR	1.1 [0.9, 1.3]		

Covariate ***	Biomarker *: Ratio [95% CI]**									
	Inflammation		Coagulant dysfunction			Endothelial dysfunction				
	CRP N=214	IL-6 N=224	MCP-1 N=224	Fibrinogen N=223	P-selectin N=224	sICAM N=224	sVCAM N=222	E-selectin N=225		
HIV disease specific variables#										
Viral load >5000 copies/mL (vs ≤400)	1.5 ⁴ [0.99, 2.28]	...	1.23 ² [1.08, 1.14]	1.42 ² [1.14, 1.77]	1.5 ³ [1.3, 1.6]
PI	1.12 ² [1.04, 1.21]
NRTI	0.83 ¹ [0.69, 0.99]
NNRTI	1.66 ¹ [1.09, 2.51]

* Biomarkers of vascular dysfunction were log [0-transformed for analysis. For presentation in the tables and text, the antilog determined for each beta coefficient and 95% CI in each model. For example, for the outcome CRP in the table above, the estimate for males vs. females was 0.94. The interpretation is that the average value of CRP in the HIV-infected is 0.94 times that in the HEU or ~9% lower in the HIV-infected.

** **Bolded** variables are significant at p≤0.05 on the F-test. When the F-test was significant at p≤0.05 then the p values are indicated for differences between the upper level and the lowest level (e.g. highest quartile versus lowest quartile for lipids) ¹p≤0.05; ²p≤0.01; ³p≤0.001; ⁴p=0.057. For BMI z, the p-value z-score is for the continuous variable.

*** All models were adjusted for age, sex, race/ethnicity, and BMI z-score. Other measures of body composition that were considered for the multivariable analysis model included: waist and hip circumference, waist:hip ratio, and percent body fat. HOMA-IR, and CD4 T lymphocyte count. The number included in each model differs due to missing variables and for CRP values greater than 10 were excluded.

Rows that have empty cells (...) show variables that were not included in the model because their associations were at p>0.10 or were not determined to be a confounder

NHW = Non-Hispanic white; NHB = Non-Hispanic black; BMI = body mass index; PI = protease inhibitor; NRTI = nucleotide reverse transcriptase inhibitor; NNRTI = non-nucleotide reverse transcriptase inhibitor; CRP = c-reactive protein; IL-6 = interleukin-6; MCP-1 = monocyte chemoattractant protein-1; sICAM = soluble intracellular cell adhesion molecule-1; sVCAM = soluble vascular cell adhesion molecule-1